Finch Therapeutics Group, Inc. (FNCHQ): Nasdaq/NYSE listing notice — Finch Therapeutics receives additional delisting notice, requests transfer to Nasdaq Capital Market

Finch Therapeutics Group, Inc.

Nasdaq issued Additional Staff Determination on May 14, 2024, for continued noncompliance with $5M MVPHS Rule.
Company failed to regain compliance by May 13, 2024 deadline; first flagged Nov 15, 2023.
Company also deemed a 'public shell'; appeal hearing held April 23, 2024, decision pending.
On May 15, 2024, Company requested transfer from Nasdaq Global Select to Nasdaq Capital Market; no guarantee of approval.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Finch Therapeutics Group, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(1)(C)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(1)(C)

Exact text from the filing

May 14, 2024, the Nasdaq Listing Qualifications Department issued an Additional Staff Determination that the Company’s continued noncompliance with the MVPHS Rule serves as an additional basis for delisting the Common Stock from The Nasdaq Global Select Market. Also as previously disclosed, the Company previously received a determination letter from the Nasdaq Listing Qualifications Department informing the Company of Nasdaq’s belief that the Company is a “public shell” under the Nasdaq criteria. The Company appealed the Nasdaq Listing Qualifications Department’s determination with respect to

View on SEC.gov

Browse all listing & compliance notices →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-141816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.